Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach.

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach.

10-41

Mar 28, 2020 06:13PM

narmac

Rank: Vice President [?]

Points: 3973 [?]

Votes: 36 Score: 3.0 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach.

in response to

Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach.

10-41

posted on Mar 31, 2020 02:23PM

,,hummmmm,,it is becoming ever increasingly more plausible and believable that our science is leading edge!,,if so,,,, what is our library of molecules worth to BP with a similar business interest?..would they not want to obtain such a vast pipeline??..hardly imo,,..this technology has to be worth,,can we say ,, many Billions!!!,,

7 Recommendations

Re: Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach.

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Re: Back to the draw­ing board for triple-neg­a­tive breast can­cer tar­gets, re­searchers pro­pose new com­bo ap­proach.

Re: Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach.